ALT

Altimmune Inc

ALT.US altimmune.com
3.29
-0.06 (-1.79%)
USD · NASDAQ
52-week range
2.56
6.44
Trading at 19% of the 52-week range
Market Cap
651.63M
P/E Ratio
0.00
Forward P/E
8.18
Book Value
2.44
Div. Yield
N/A
% Institutions
77.76%
% Insiders
0.416%

1 Year

-10.4%

3 Year

+35.4%

10 Year

+822,400.0%
Description

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Company Information

Company Name
Altimmune Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US02155H2004
CIK: 0001326190
CUSIP: 42224H203
Currency: USD
Full Time Employees: 57
Phone: 240 654 1450
Fiscal Year End: December
IPO Date: Oct 06, 2005
Description:

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Address:

910 Clopper Road, Gaithersburg, MD, United States, 20878

People

Directors & Officers

Name Title Year Born
Mr. Jerome Benedict Durso Chairman, CEO & President 1968
Dr. M. Scot Roberts Ph.D. Chief Scientific Officer 1959
Dr. Christophe Arbet-Engels M.B.A., M.D., Ph.D. Chief Medical Officer 1963
Mr. Gregory L. Weaver CPA, M.B.A. Chief Financial Officer 1956
Mr. Andrew Shutterly M.S. Principal Financial & Accounting Officer and Corporate Controller 1988
Mr. Bertrand Georges Ph.D. Chief Technology Officer NA
Mr. Luis Sanay C.F.A. Vice President of Investor Relations NA
Mr. Tony Blandin B.S. Vice President of Quality & Compliance Management NA
Ms. Robin E. Abrams J.D. Chief Legal Officer & Corporate Secretary 1964
Mr. Raymond M. Jordt M.B.A., M.S. Chief Business Officer 1973

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Mar 06, 2026 Gregory L Weaver N/A Purchase 5.00K $3.54 $17.70K
Mar 06, 2026 Jerome Benedict Durso N/A Purchase 20.00K $3.54 $70.80K
Jan 08, 2026 Wayne Pisano N/A Purchase 5.00K $4.08 $20.40K
Dec 29, 2025 Diane Jorkasky N/A Purchase 527.00 $3.80 $2.00K
Dec 23, 2025 John Gill N/A Purchase 12.50K $4.10 $51.25K
Dec 22, 2025 Jerome Benedict Durso N/A Purchase 12.50K $4.13 $51.63K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Deep Track Capital, LP 19.25M Jun 30, 2026 9.90% $0.85 0.00%
BlackRock Inc 12.80M Mar 31, 2026 6.58% $0.00 31.85%
TCG Crossover Management, LLC 10.00M Jun 30, 2026 5.14% $0.73 0.00%
State Street Corp 7.15M Mar 31, 2026 3.67% $0.00 39.57%
Vanguard Capital Management, LLC 5.66M Mar 31, 2026 2.91% $0.00 0.00%
Vanguard Portfolio Management, LLC 5.38M Mar 31, 2026 2.77% $0.00 0.00%
Marshall Wace Asset Management Ltd 4.02M Mar 31, 2026 2.07% $0.01 335.41%
Millennium Management LLC 3.31M Jun 30, 2026 1.70% $0.00 1.56%
Geode Capital Management, LLC 3.11M Mar 31, 2026 1.60% $0.00 35.54%
Trails Edge Capital Partners, LP 2.66M Jun 30, 2026 1.37% $1.28 0.00%
Alyeska Investment Group, L.P. 2.64M Mar 31, 2026 1.36% $0.02 0.00%
Two Sigma Investments LLC 2.48M Mar 31, 2026 1.27% $0.01 95.85%
Nuveen, LLC 2.33M Mar 31, 2026 1.20% $0.00 87.64%
Great Point Partners LLC 1.74M Jun 30, 2026 0.90% $1.00 0.00%
The Goldman Sachs Group Inc 1.35M Mar 31, 2026 0.69% $0.00 0.10%
Susquehanna International Group, LLP 1.33M Mar 31, 2026 0.68% $0.00 -3.15%
Northern Trust Corp 996.72K Mar 31, 2026 0.51% $0.00 39.21%
UBS Group AG 904.77K Mar 31, 2026 0.47% $0.00 40.92%
Vanguard Fiduciary Trust Co 869.32K Mar 31, 2026 0.45% $0.00 0.00%
Morgan Stanley - Brokerage Accounts 775.26K Mar 31, 2026 0.40% $0.00 -42.99%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 State Street® SPDR® S&P® Biotech ETF 8.54M 4.39% ▼ 1.06% Aug 31, 2026
2 Vanguard MStar Total Stk Mkt Idx Invest 5.75M 2.96% ▲ 0.00% Jul 31, 2026
3 iShares Russell 2000 ETF 5.08M 2.61% ▼ 0.57% Aug 31, 2026
4 Vanguard Strategic Equity Inv 2.67M 1.37% ▲ 45.55% Jun 30, 2026
5 Vanguard Institutional Extnd Mkt Idx Tr 2.24M 1.15% ▲ 0.23% Jul 31, 2026
6 Fidelity Small Cap Index 2.16M 1.11% ▲ 64.35% Jun 30, 2026
7 Nuveen Quant Small Cap Equity R6 1.85M 0.95% ▼ 1.94% Jun 30, 2026
8 iShares Russell 2000 Value ETF 1.85M 0.95% ▼ 0.23% Aug 31, 2026
9 Fidelity Enhanced Small Cap Core ETF 1.40M 0.72% ▲ 0.29% Aug 31, 2026
10 iShares Biotechnology ETF 1.37M 0.70% ▲ 0.80% Aug 31, 2026

Financial Highlights

Market Cap: $651.63M
EBITDA: $-98.63M
PEG Ratio: $32.62
Book Value: $2.44
Earnings/Share: $-0.76
Profit Margin: 0.00%
Operating Margin: -318,493.55%
ROA (TTM): -17.20%
ROE (TTM): -28.88%
Revenue (TTM): $31.00K
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 420.00%

Valuation Metrics

Enterprise Value: $359.43M
Trailing P/E: 0.00
Forward P/E: 8.18

Shares Statistics

Shares Outstanding: 194.52M
Shares Float: 164.39M
% Insiders: 0.416%
% Institutions: 77.76%
Short % Float: 26.24%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$41.00K
Cost of Goods Sold
adjust
$-112.00K
Gross Profit
subtotal
$41.00K
SG&A
adjust
$-28.10M
R&D
adjust
$-66.43M
Operating Income
subtotal
$-94.49M
Other / Non-Operating Items
adjust
$6.40M
Net Income
subtotal
$-88.09M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ALT.US!